Creo Medical Group plc announced the following change to the Board and strengthening of the Senior Management team. David Woods, Non-Executive Director, has been appointed as Chief Commercial Officer ('CCO'), with effect from 1 August 2020. David has extensive experience in the med-tech sector and joins the Company in his new full-time executive role based in the USA, having previously been the President and CEO of PENTAX Americas and M&A Director of HOYA Group PENTAX Medical. As the Company prepares to accelerate and progress commercially, a President of Sales, Service and Commercial Operations has also been appointed in both the USA and the Asia-Pacific regions to provide a substantial presence, gain market share and revenue within these regions, and give healthcare professionals access to much needed advanced medical technologies and instruments. These appointments, along with other recent appointments, bring with them experience from companies such as Medtronic, Covidien, BARRX, J&J, Pentax, Philips Healthcare, US Endoscopy, and BTG Group. Creo has also made further senior appointments for US Sales, Service and Commercial operations, Wider EMEA Sales, Global Marketing and Product Management, including marketing communications, Clinical professionals, and Professional Education.